ACAD FY 2021 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

ACADACADIA Pharmaceuticals Inc.

$4B

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$484M+9.6% YoY

Gross Profit

$465M96.0% margin

Operating Income

-$170M-35.2% margin

Net Income

-$168M-34.7% margin

EPS (Diluted)

$-1.05

Cash Flow

Operating Cash Flow

-$126M

Free Cash Flow

-$127M

Stock-Based Comp.

$64M

Balance Sheet

Total Assets

$700M

Total Liabilities

$159M

Stockholders' Equity

$541M

Cash & Equivalents

$147M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$484M	$442M	+9.6%
Gross Profit	$465M	$421M	+10.4%
Operating Income	-$170M	-$287M	+40.5%
Net Income	-$168M	-$282M	+40.4%